Cerecin forges strategic partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.

Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding with A*STAR’s Institute of Molecular and Cell Biology.